FDA Approves Shorter Monitoring for First Two Tarlatamab Doses in ES-SCLC

The FDA has approved a label update for tarlatamab in extensive-stage small cell lung cancer that reduces the monitoring time for the first two doses from 22-24 hours to 6-8 hours, with added next-day patient assessments to maintain safety.

This Wire brief sits within Fusion42's coverage of Biotech, and 2 sources have reported it between 14 Sep 2026 and 15 Sep 2026.